Proscia Concentriq vs Visiopharm
A US lab moving to digital primary diagnosis goes to Proscia. K230839 covers the Hamamatsu NanoZoomer S360MD, and K261380 adds the Leica Aperio GT 450 DX and cloud deployment. A UK or EU lab buying scoring apps for ER, PR, HER2 and Ki-67 goes to Visiopharm, whose apps the vendor says are IVDR certified.
A lab already scanning on Grundium hardware drops Proscia, because Visiopharm lists that pairing and Proscia's cleared pairings name only Hamamatsu and Leica.
Both vendors are in the middle of a sale. Agilent announced its up-to-$270 million agreement to acquire Proscia on October 13, 2026, with closing expected early in Agilent's fiscal 2027. Grundium Oy announced its Visiopharm acquisition on May 21, 2026. How either deal changes the roadmap is unknown. A pharma biomarker team can buy either, since Proscia's Life Sciences line and Visiopharm's research-use platform target the same work.
Pathology · Reviewed November 1, 2026
Proscia Concentriq
by Proscia
Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.
Visiopharm
by Visiopharm
Pathology image-analysis software with CE-IVD apps for breast, lung and prostate biomarkers and a research-use platform.
When to pick each one
Proscia Concentriq
- Cleared with Hamamatsu S360MD and Leica GT 450 DX
- Cloud deployment in the August 2026 clearance
- SOC 2 Type II and ISO 27001
Visiopharm
- Vendor-stated IVDR apps for ER, PR, HER2, Ki-67
- Grundium scanner pairing listed
- ISO 13485:2016 certificate
Score
Each row shows points earned of points available under the published rubric.
Proscia Concentriq
40of 100
Visiopharm
43of 100
| Dimension | Proscia Concentriq | Visiopharm | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 0 / 18 | +18 |
| HIPAA / SOC2 / BAA | 6 / 10 | 0 / 10 | +6 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 0 / 21 | 21 / 21 | -21 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 7.8 / 7.8 | -7.8 |
| Funding & adoption signal | 8.4 / 12 | 6 / 12 | +2.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Proscia Concentriq
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Demo request only. |
Visiopharm
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
Proscia Concentriq
FDA decisions
K261380 (opens in new tab)510(k)2026-08-05
Concentriq AP-Dx
K230839 (opens in new tab)510(k)2024-02-08
Concentriq Dx (marketed as Concentriq AP-Dx)
Visiopharm
FDA decisions
No FDA decision cited in our research as of October 20, 2026.
Peer-reviewed
5 PubMed records name Visiopharm.
- Inter-rater agreement of HER2-low scores between expert breast pathologists and the Visiopharm digital image analysis application (HER2 APP, CE2797). (opens in new tab)
- Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial. (opens in new tab)
- Head-to-Head Comparison of 2 Artificial Intelligence Tools for Detecting Lymph Node Metastases in Whole-Slide Pathology Images Within and Beyond Their Intended Use. (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Proscia Concentriq | Visiopharm |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | n/a | DK |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.